Efficacy Analysis of Integrative Therapy Based on Fuzheng Jiedu Xiaoji Formula（ 扶正解毒消积方） for Primary Liver Cancer

GU Lili; LIU Huimin; ZHOU Xiaobing; LIU Yao; GAO Fangyuan; WANG Xianbo

doi:10.13288/j.11-2166/r.2014.07.011

您当前的位置：

首页 >

文章列表页 >

Efficacy Analysis of Integrative Therapy Based on Fuzheng Jiedu Xiaoji Formula（扶正解毒消积方） for Primary Liver Cancer

更新时间：2021-11-17

- Efficacy Analysis of Integrative Therapy Based on Fuzheng Jiedu Xiaoji Formula（扶正解毒消积方） for Primary Liver Cancer
- Journal of Traditional Chinese Medicine Vol. 55, Issue 7, Pages: 576-579(2014)
- 作者机构：
  
  1. 北京中医药大学东直门医院
  2. 首都医科大学附属北京地坛医院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2014.07.011
  CLC： R735.7
- Published：2014
- 稿件说明：
移动端阅览
[1]谷莉莉,刘慧敏,周小兵,刘尧,高方媛,王宪波.基于扶正解毒消积方的中西医结合方案治疗原发性肝癌的疗效分析[J].中医杂志,2014,55(07):576-579.

GU Lili, LIU Huimin, ZHOU Xiaobing, et al. Efficacy Analysis of Integrative Therapy Based on Fuzheng Jiedu Xiaoji Formula（扶正解毒消积方） for Primary Liver Cancer[J]. Journal of Traditional Chinese Medicine2014, 55(7): 576-579.
[1]谷莉莉,刘慧敏,周小兵,刘尧,高方媛,王宪波.基于扶正解毒消积方的中西医结合方案治疗原发性肝癌的疗效分析[J].中医杂志,2014,55(07):576-579. DOI： 10.13288/j.11-2166/r.2014.07.011.

GU Lili, LIU Huimin, ZHOU Xiaobing, et al. Efficacy Analysis of Integrative Therapy Based on Fuzheng Jiedu Xiaoji Formula（扶正解毒消积方） for Primary Liver Cancer[J]. Journal of Traditional Chinese Medicine2014, 55(7): 576-579. DOI： 10.13288/j.11-2166/r.2014.07.011.

摘要

目的探讨基于扶正解毒消积方的中西医结合方案对原发性肝癌的临床疗效及预后的影响。方法将68例原发性肝癌患者分为中西医结合组（西医综合治疗+扶正解毒消积方加减）和西医治疗组（西医综合治疗）各34例

观察两组治疗前后肝功能、甲胎蛋白和凝血酶原活动度情况以及实体瘤疗效、肝功能Child-Pugh分级及生存率。结果治疗后中西医结合组患者血清白蛋白（ALB）水平较治疗前明显升高

且高于西医治疗组治疗后（P<0.05）。治疗后中西医结合组实体瘤缓解率（33.33%）和稳定率（87.88%）均高于西医治疗组的17.24%和62.68%（P<0.05）。两组治疗后Child-Pugh分级比较差异无统计学意义（P>0.05）。治疗后中西医结合组生存率为97.1%

西医治疗组为85.3%

两组比较差异无统计学意义（P>0.05）。结论基于扶正解毒消积方的中西医结合方案治疗能够控制原发性肝癌的复发和进展

提高患者的生存时间。

Abstract

Objective To research the efficacy and prognosis of integrative therapy based on Fuzheng Jiedu Xiaoji Formula（ vital qi-supporting

toxin-resolving and accumulations-dispersing formula

FJXF） for primary liver cancer（PLC）. Methods Totally 68 cases of PLC were randomized into the integrative medicine group（comprehensive therapy + modified FJXF） and western medicine group（comprehensive therapy）

with 34 in each. The liver function

alpha-fetoprotein（AFP）

prothrombin activity

efficacy in solid tumors

Child-Pugh classification of severity of liver disease and cumulative survival rate were observed before and after treatment. Results The level of serum albumin（ALB） was significantly increased in the integrative medicine group after treatment（ P < 0. 05）. The ALB level in the integrative medicine group was significantly higher than that in the western medicine group after treatment（P < 0. 05）. The response rate i. e. 33. 33% and stable rate i. e. 87. 88% of solid tumor in the integrative medicine group were significantly higher than those i. e. 17. 24% and 62. 68% respectively in the western medicine group after treatment（P < 0. 05）. There was no significant difference between groups in Child-Pugh grades at each time point（P > 0. 05）. The survival rate in the integrative medicine group was 97. 1% higher than 85. 3% in the western medicine group

but the difference was not significant（P > 0. 05）. Conclusion Integrative therapy based on FJXF can control recurrence and progression of PLC and improve the survival rate.

关键词

Keywords

references

查看原文

Views

260

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

The Effects of Huqi Zhengxiao Formula （槲芪癥消方） on the Survival Rate and Quality of Life of Patients of Stage Ⅲ Hepatitis B-Associated Primary Liver Cancer with Syndrome of Healthy Qi Deficiency， Toxic Stasis Accumulation After Transcatheter Arterial Chemoembolisation Treatment

The Effect of Fufang Banmao Capsule （复方斑蝥胶囊） Combined with Western Medicine on the Survival of Patients with Primary Liver Cancer and Spleen Deficiency and Blood Stasis Syndrome： A Retrospective Study

Pathomechanism and Treatment Strategy of Phlegm and Blood Stasis in the Immunosuppressive Tumor Microenvironment of Liver Cancer

Effect of Shipi Xiaoji Beverage（实脾消积饮）-containing Serum on Mitochondrial Dynamics Imbalance and Ferroptosis of Liver Cancer HepG2 Cells

Cinobufagin Combined with Thalidomide/Dexamethasone Regimen in the Treatment of Patients with Newly Diagnosed Multiple Myeloma of Phlegm and Stasis Obstruction： A Retrospective Study

Related Author

XU Wenjun

LI Jingying

WANG Xiaojun

ZHANG Chun

Jie HOU

Ke SHI

Yao LIU

Jialiang CHEN

Related Institution

Peking University Third Hospital

Beijing Youan Hospital， Capital Medical University

Dongzhimen Hospital，Beijing University of Chinese Medicine

Beijing Ditan Hospital，Capital Medical University

Cheeloo College of Medicine，Shandong University

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰